NCT06742138Not yet recruitingPhase 3
A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase III Clinical Study to Evaluate QL2109/ DARZALEX FASPRO® in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Enrollment
- 284
- Primary Endpoint
- Percentage of Participants With Very Good Partial Response (VGPR) or Better
Study Overview
Brief Summary
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants with relapsed or refractory Multiple Myeloma.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Males and females at least 18 years of age.
- •Subject must have measurable disease of MM as defined by the criteria below:Serum M-protein level ≥0.5 g/dL or urine M-protein level ≥200 mg/24 hours; or Light chain multiple myeloma, for subjects without measurable disease in the serum or urine: Serum immunoglobulin free light chain (FLC) ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
- •Subjects must have received prior antimyeloma treatment. The prior treatment must have included both a PI- and lenalidomide-containing regimens. Subjects who received only 1 line of prior treatment must have demonstrated PD on or within 60 days of completion of the lenalidomide containing regimen (ie, lenalidomide refractory).
- •Subjects must have documented evidence of PD based on the investigator's determination of response as defined by the modified IMWG criteria on or after the last regimen.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of ≤
- •For subjects experiencing toxicities resulting from previous therapy, the toxicities must be resolved or stabilized to ≤Grade
- •Any of the following laboratory test results during Screening:
- •Absolute neutrophil count ≥1.0 × 109/L;
- •Hemoglobin level ≥75 g/L (≥4.65 mmol/L); (transfusions are not permitted to reach this level);
- •Platelet count ≥75 × 109/L in subjects in whom <50% of bone marrow nucleated cells are plasma cells and platelet count ≥50 x 109/L in subjects in whom ≥50% of bone marrow nucleated cells are plasma cells;
- •Alanine aminotransferase (ALT) level ≤2.5 times the upper limit of normal (ULN);Aspartate aminotransferase (AST) level ≤2.5 x ULN;
- •Total bilirubin level ≤1.5 x ULN, (except for Gilbert Syndrome: direct bilirubin ≤1.5 × ULN);
- •Creatinine clearance ≥30 mL/min
- •Serum calcium corrected for albumin ≤14.0 mg/dL (≤3.5 mmol/L), or free ionized calcium ≤ 6.5 mg/dL (≤1.6 mmol/L).
Exclusion Criteria
- •Subject has plasma cell leukemia (>2.0 × 109/L circulating plasma cells by standard differential) or Waldenström's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or amyloidosis.
- •History of malignancy (other than MM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesion that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years).
- •Clinical signs of meningeal involvement of MM.
- •Previous therapy with any anti-CD38 monoclonal antibody.
- •Previous exposure to pomalidomide.
- •Subject has received antimyeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 mg/day for a maximum of 4 days) for palliative treatment before Cycle 1, Day 1 (C1D1).
- •Previous allogenic stem cell transplant; or autologous stem cell transplantation (ASCT) within 12 weeks before C1D
- •Subject has had major surgery within 2 weeks before randomization, or has not fully recovered from an earlier surgery, or has surgery planned during the time the subject is expected to participate in the study or within 2 weeks after the last dose of study drug administration.
- •Ongoing ≥ Grade 2 peripheral neuropathy.
- •Subject had ≥Grade 3 rash during prior therapy.
- •Pregnant or nursing women.
Arms & Interventions
Pomalidomide Plus(+) QL2109 + Dexamethasone
Experimental
Intervention: QL2109 (Drug)
Pomalidomide Plus(+) QL2109 + Dexamethasone
Experimental
Intervention: Pomalidomide (Drug)
Pomalidomide Plus(+) QL2109 + Dexamethasone
Experimental
Intervention: Dexamethasone (Drug)
Pomalidomide + DARZALEX FASPRO® + Dexamethasone
Active Comparator
Intervention: Pomalidomide (Drug)
Pomalidomide + DARZALEX FASPRO® + Dexamethasone
Active Comparator
Intervention: Dexamethasone (Drug)
Pomalidomide + DARZALEX FASPRO® + Dexamethasone
Active Comparator
Intervention: DARZALEX FASPRO® (Drug)
Outcomes
Primary Outcomes
Percentage of Participants With Very Good Partial Response (VGPR) or Better
Time Frame: from baseline to week 24
VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response\[sCR\]) according to the IMWG criteria during or after the study treatment.
Secondary Outcomes
- Percentage of Participants With Very Good Partial Response (VGPR) or Better(from baseline to week 12 and week 48)
- Overall Response Rate(from baseline to week 24 and week 48)
- Overall survival at 18 months(from baseline to 18 months)
Investigators
Similar Trials
Completed
Phase 3
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.Breast CancerNCT04629846Qilu Pharmaceutical Co., Ltd.517
Unknown
Phase 3
Clinical Trail of Tang-min-Ling Pills in Type 2 Diabetes MellitusType 2 DiabetesNCT01087242Guang'anmen Hospital of China Academy of Chinese Medical Sciences480
Completed
Phase 3
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelPulmonary Disease, Chronic ObstructiveNCT04133909GlaxoSmithKline806
Completed
Phase 3
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe AsthmaAsthmaNCT02814643AstraZeneca103
Completed
Phase 3
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)AsthmaNCT03186209AstraZeneca695